A citation-based method for searching scientific literature

Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson, Ross L Levine, Francesco Lo-Coco, Tomoki Naoe, Dietger Niederwieser, Gert J Ossenkoppele, Miguel Sanz, Jorge Sierra, Martin S Tallman, Hwei-Fang Tien, Andrew H Wei, Bob Löwenberg, Clara D Bloomfield. Blood 2017
Times Cited: 2071







List of co-cited articles
490 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
28

Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Nicola D Roberts, Nicola E Potter, Michael Heuser, Felicitas Thol, Niccolo Bolli,[...]. N Engl J Med 2016
27

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013
17

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux,[...]. N Engl J Med 2020
227
16

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, Kristina Laumann, Susan Geyer, Clara D Bloomfield, Christian Thiede, Thomas W Prior, Konstanze Döhner, Guido Marcucci,[...]. N Engl J Med 2017
821
15

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D DiNardo, Keith Pratz, Vinod Pullarkat, Brian A Jonas, Martha Arellano, Pamela S Becker, Olga Frankfurt, Marina Konopleva, Andrew H Wei, Hagop M Kantarjian,[...]. Blood 2019
599
15

Acute Myeloid Leukemia.
Hartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield. N Engl J Med 2015
12

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K Hills, Christopher S Hourigan,[...]. Blood 2018
390
12

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Jay P Patel, Mithat Gönen, Maria E Figueroa, Hugo Fernandez, Zhuoxin Sun, Janis Racevskis, Pieter Van Vlierberghe, Igor Dolgalev, Sabrena Thomas, Olga Aminova,[...]. N Engl J Med 2012
10

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
R Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, Peter V Grauman, Sarah Shareef, Steven L Allen, Arnaud Pigneux, Meir Wetzler, Robert K Stuart, Harry P Erba,[...]. Blood 2015
384
10

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
David Grimwade, Robert K Hills, Anthony V Moorman, Helen Walker, Stephen Chatters, Anthony H Goldstone, Keith Wheatley, Christine J Harrison, Alan K Burnett. Blood 2010
10

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, Thomas Büchner, Cheryl L Willman, Elihu H Estey, Charles A Schiffer, Hartmut Doehner, Martin S Tallman, T Andrew Lister,[...]. J Clin Oncol 2003
10

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
Christopher S Hourigan, Laura W Dillon, Gege Gui, Brent R Logan, Mingwei Fei, Jack Ghannam, Yuesheng Li, Abel Licon, Edwin P Alyea, Asad Bashey,[...]. J Clin Oncol 2020
79
11

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L Lin, Roland B Walter, Anoop Enjeti, Ing Soo Tiong, Michael Savona, Sangmin Lee,[...]. J Clin Oncol 2019
248
9

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R Baer, Richard A Larson, Celalettin Ustun,[...]. N Engl J Med 2019
263
9

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Mojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, François G Kavelaars, Adil Al Hinai, Annelieke Zeilemaker, Claudia A J Erpelinck-Verschueren, Patrycja L Gradowska, Rosa Meijer, Jacqueline Cloos,[...]. N Engl J Med 2018
299
9

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner, Elihu H Estey, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Alan K Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A Larson,[...]. Blood 2010
9

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
C D DiNardo, I S Tiong, A Quaglieri, S MacRaild, S Loghavi, F C Brown, R Thijssen, G Pomilio, A Ivey, J M Salmon,[...]. Blood 2020
101
8

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Martin S Tallman, Eunice S Wang, Jessica K Altman, Frederick R Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E Coutre, Marcos De Lima, Amir T Fathi, Melanie Fiorella,[...]. J Natl Compr Canc Netw 2019
126
8

Defining the intensity of conditioning regimens: working definitions.
Andrea Bacigalupo, Karen Ballen, Doug Rizzo, Sergio Giralt, Hillard Lazarus, Vincent Ho, Jane Apperley, Shimon Slavin, Marcelo Pasquini, Brenda M Sandmaier,[...]. Biol Blood Marrow Transplant 2009
930
7

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.
Jan J Cornelissen, Alois Gratwohl, Richard F Schlenk, Jorge Sierra, Martin Bornhäuser, Gunnar Juliusson, Zdenek Råcil, Jacob M Rowe, Nigel Russell, Mohamad Mohty,[...]. Nat Rev Clin Oncol 2012
248
7

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
John C Byrd, Krzysztof Mrózek, Richard K Dodge, Andrew J Carroll, Colin G Edwards, Diane C Arthur, Mark J Pettenati, Shivanand R Patil, Kathleen W Rao, Michael S Watson,[...]. Blood 2002
7

Assessment of Minimal Residual Disease in Standard-Risk AML.
Adam Ivey, Robert K Hills, Michael A Simpson, Jelena V Jovanovic, Amanda Gilkes, Angela Grech, Yashma Patel, Neesa Bhudia, Hassan Farah, Joanne Mason,[...]. N Engl J Med 2016
395
7

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Monique Terwijn, Wim L J van Putten, Angèle Kelder, Vincent H J van der Velden, Rik A Brooimans, Thomas Pabst, Johan Maertens, Nancy Boeckx, Georgine E de Greef, Peter J M Valk,[...]. J Clin Oncol 2013
281
7

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Andreas Burchert, Gesine Bug, Lea V Fritz, Jürgen Finke, Matthias Stelljes, Christoph Röllig, Ellen Wollmer, Ralph Wäsch, Martin Bornhäuser, Tobias Berg,[...]. J Clin Oncol 2020
60
11

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer,[...]. Blood 2002
7

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L Sorror, Michael B Maris, Rainer Storb, Frederic Baron, Brenda M Sandmaier, David G Maloney, Barry Storer. Blood 2005
6

Revised international prognostic scoring system for myelodysplastic syndromes.
Peter L Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo Garcia-Manero, Francesc Solé, John M Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus,[...]. Blood 2012
6

'Acute myeloid leukemia: a comprehensive review and 2016 update'.
I De Kouchkovsky, M Abdul-Hay. Blood Cancer J 2016
394
6

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen A Strickland, Donna Hogge, Scott R Solomon,[...]. J Clin Oncol 2018
314
6

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
Sylvie D Freeman, Paul Virgo, Steve Couzens, David Grimwade, Nigel Russell, Robert K Hills, Alan K Burnett. J Clin Oncol 2013
200
6

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Jorge E Cortes, Samer Khaled, Giovanni Martinelli, Alexander E Perl, Siddhartha Ganguly, Nigel Russell, Alwin Krämer, Hervé Dombret, Donna Hogge, Brian A Jonas,[...]. Lancet Oncol 2019
124
6

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, Sudhir Tauro, Gunes Gundem, Peter Van Loo, Chris J Yoon, Peter Ellis, David C Wedge, Andrea Pellagatti,[...]. Blood 2013
6

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017
638
6

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller-Tidow, Utz Krug, Claudia D Baldus, Christian H Brandts, Volker Kunzmann, Hermann Einsele,[...]. Lancet Oncol 2015
221
6

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
524
6

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, Courtney D DiNardo, Jan Novak, Kamel Laribi, Inho Kim, Don A Stevens, Walter Fiedler, Maria Pagoni,[...]. Blood 2020
107
6

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval G Daver, Tapan M Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado,[...]. Lancet Haematol 2020
47
12

Functional genomic landscape of acute myeloid leukaemia.
Jeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, Beth Wilmot, Stephen E Kurtz, Samantha L Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Melissa Abel,[...]. Nature 2018
272
5


Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Tobias Herold, Maja Rothenberg-Thurley, Victoria V Grunwald, Hanna Janke, Dennis Goerlich, Maria C Sauerland, Nikola P Konstandin, Annika Dufour, Stephanie Schneider, Michaela Neusser,[...]. Leukemia 2020
29
17

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Sylvie Castaigne, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Dominique Bordessoule, Jean-Noel Bastie, Ollivier Legrand, Xavier Thomas, Pascal Turlure, Oumedaly Reman,[...]. Lancet 2012
534
5

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
Philippe Armand, Haesook T Kim, Brent R Logan, Zhiwei Wang, Edwin P Alyea, Matt E Kalaycio, Richard T Maziarz, Joseph H Antin, Robert J Soiffer, Daniel J Weisdorf,[...]. Blood 2014
443
5

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki, Brent L Wood, Megan Othus, Jerald P Radich, Anna B Halpern, Yi Zhou, Marco Mielcarek, Elihu H Estey, Frederick R Appelbaum, Roland B Walter. J Clin Oncol 2016
235
5

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop,[...]. Blood 2018
103
5


Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
Matthew S Davids, Haesook T Kim, Pavan Bachireddy, Caitlin Costello, Rebecca Liguori, Alexandra Savell, Alexander P Lukez, David Avigan, Yi-Bin Chen, Peter McSweeney,[...]. N Engl J Med 2016
292
5

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
Nicholas J Short, Marina Konopleva, Tapan M Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D DiNardo, Naval Daver. Cancer Discov 2020
44
11

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Patrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, Christopher S Hourigan, Karolyn A Oetjen, Jorge E Cortes, Farhad Ravandi, Elias J Jabbour, Zainab Al-Hamal, Marina Konopleva,[...]. Cancer 2019
89
5

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Alan K Burnett, Nigel H Russell, Robert K Hills, Ann E Hunter, Lars Kjeldsen, John Yin, Brenda E S Gibson, Keith Wheatley, Donald Milligan. J Clin Oncol 2013
214
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.